Kidney transplant patients may get heart and kidney boost from diabetes drug
NCT ID NCT04906213
First seen Jan 08, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tested the drug empagliflozin in 20 kidney transplant recipients, some with type 2 diabetes and some without. The goal was to see if the drug could improve kidney function, heart structure, and blood sugar levels. Participants took either empagliflozin or a placebo for a period, and researchers monitored changes through blood tests, urine tests, and heart imaging.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.